Board of Directors
Robert Coradini, Chairman
Robert Coradini has served as a member of our Board of Directors since December 2011 and as our interim CEO as of June, 15 2013. Mr. Coradini currently serves as an expert to the medical device and biotechnology industry. Prior to this and since 1996 Mr. Coradini served in various executive capacities at several Johnson & Johnson (“J&J”) Companies. From June 2005 to May 2009, Mr. Coradini served as President of New Ventures for J&J Consumer Products Company which also included leading and growing OrthoNeutrogena (aka OrthoDermatologics), a leader in dermatology care, from January 2006 thru May 2009. From January 2003 through June 2005, Mr. Coradini served as President of CardioVations/Ethicon, a J&J Company involved with cardiac surgery and tissue management. From June 2000 to January 2003 Mr. Coradini was President of Lifescan, a J&J Company that provides medical devices to the diabetes market. Before Lifescan, Mr. Coradini was head of Business Development for J&J’s Medical Devices & Diagnostic Group and before that President of Cordis Endovascular. Prior to J&J, Mr. Coradini was with General Electric for ten years, seven of which were with GE Medical Systems. Mr. Coradini currently serves on the Board of Directors of WaferGen BioSystems and Chairs its Nominating and Governance Committee and is a member of its Compensation Committee.
Rose Crane was appointed as President, Chief Executive Officer and a Director as of November 11, 2013. Most recently Rose was a Partner at Appletree Partners where she was responsible for assessing and recommending products to build the Appletree portfolio, consisting of pharmaceutical products, medical devices and healthcare services. Previously, Rose was Chief Executive Officer and President of Epocrates, where she developed the strategic plan to advance and promote growth at the company. She also organized and directed the efforts for a successful IPO for Epocrates in 2011. Rose served as Company Group Chairman of OTC/Nutritionals at Johnson & Johnson leading the largest worldwide OTC company. She also spent 20 years of her career at Bristol-Myers Squibb, most recently as President of US Primary Care where she managed an operating unit with annual sales of $7.5 billion.
Tony Dimun brings over 30 years of successful operational, business development, and financial experience in the healthcare marketplace. Since 2001, Tony has served as Chairman of Nascent Enterprises, LLC, a group of medical industry entrepreneurs focused on successful commercialization of promising medical device inventions. From 1987 to 2001, Tony served as Executive Vice President & Chief Financial Officer of Vital Signs, Inc., a publicly held anesthesia, respiratory and sleep apnea medical device business, providing growth strategies to enhance the Company’s value through highly focused bolt on acquisitions. Vital Signs was sold to GE Medical in 2008 for $1B net of $140 cash on the balance sheet.
During the last 20 years, Tony has been a founding member, investor and mentor to several emerging growth medical enterprises that have matured to commercial status. Of these enterprises, four became public companies and eleven were acquired. Tony has been a director of several public companies including Vital Signs, Bionx Implants, Colorado MedTech, Photomedix, ISS Surgical Systems and numerous private companies in the healthcare industry. He has served on the Board of Advisors of the Rutgers University Technology Center & the Biomaterial Institute of Rutgers University, and through Nascent Enterprises, he provides the University of Pennsylvania with entrepreneurial assistance to commercialize Penn’s medical technology. Prior to 1991, Mr. Dimun held positions as a Certified Public Accountant with national accounting firms and served as Senior VP for an international merchant banking firm specializing in mergers & acquisitions.
Anne Egger was elected as a member of our Board of Directors in June 2009 and has been a consultant to the Company since March 2009. Ms. Egger has served as Vice President of Sales and Marketing of TopMD, a dermatology products company, since March 2012. Since March 2009, Ms. Egger has been the owner/director of AME Enterprises, LLC, a pharmaceutical consulting company. From October 1988 until her retirement in March of 2009, Ms. Egger served as head of the U.S. Sales and Marketing division of Galderma Laboratories, a joint venture between Nestlé and L’Oréal. Ms. Egger was also an Industry Adjunct member of the American Academy of Dermatology and a member of the American Society of Dermatologic Surgeons Industry.
Mark Fabiani was appointed as a member of our Board of Directors in December 2011. Mr. Fabiani is a Principal of Mark Fabiani LLC, a crisis management consulting firm, where he has served since 1997. Mr. Fabiani was formerly Special Counsel to President Clinton, Deputy Campaign Manager for Vice President Al Gore, and Deputy Assistant Attorney General at the Justice Department. Mr. Fabiani is an expert in public relations.
Mindy Meads was elected a member of our Board of Directors in April 2012. In October, 2012, Ms. Meads was appointed a Director of Wet Seal, Inc., a teen specialty retailer of fashionable and contemporary apparel and accessory items. Ms. Meads is an experienced CEO with 35 years of experience in the global apparel industry. From 2009 to 2011 she was the Co-CEO of Aeropostale Inc., a teen specialty retailer with more than 900 stores. From 2007 to 2009 she served as President and Chief Merchant Officer. In 2006 Ms. Meads was Chief Executive Officer and President of Victoria Secret Direct, an e-commerce and catalogue retailer. Prior to that, Ms. Meads was at Lands’ End from 1990 to 2005, serving as President and Chief Executive Officer from 2003 to 2005. She has held a variety of Senior Executive Merchandising roles with several leading retailers. She is a former Director of the Federal Reserve Bank for the 7th District, and sits on the board of several not-for profit companies. She currently serves on the Board of Trustees of The Masters School, and is a member of The Committee of 200, a business women’s leadership organization.
Darrell S. Rigel, MD, MS
Darrell S. Rigel, MD is a Clinical Professor of Dermatology at New York University Medical Center. His research is in the areas of early detection of malignant melanoma and associated risk factors and prognosis for and other skin cancers and factors leading to aging of the skin. He is the author of numerous articles and abstracts in professional journals as well as lead editor of Cancer of the Skin, the major textbook in this field.
Dr. Rigel has served as President of the American Academy of Dermatology and also served for 9 years as a Director of the American Board of Dermatology. He is a Past President of the American Society for Dermatologic Surgery and the American Dermatological Association. He also serves as a Vice-Chair of the MIT Educational Counselor program
Dr. Rigel has made over 800 presentations at medical and governmental policy conferences worldwide and has chaired numerous national and international conferences and symposia. He has testified before Congress regarding the effects of ozone depletion on skin cancer. He often appears on National television including CNN, ABC, FOX, NBC and CBS and his research and opinions are regularly cited in the New York Times, Wall Street Journal and many other national magazines and newspapers
Dr. Rigel has received numerous awards and honors including the American Cancer Society’s National Honor Citation for Skin Cancer Programs and Presidential Citations from the American Academy of Dermatology and American Society for Dermatologic Surgery for public education programs in skin cancer.
Dr. Rigel is a graduate of MIT with a BS in Management Information Sciences, an MS (MBA) from the Sloan School of Management at MIT and received his MD from George Washington University. He attended Cornell University Medical Center for Internship in Internal Medicine and completed his training at NYU where he was Resident, Chief Resident, NIH Training Fellow and Dermatology Surgery Fellow.
In addition, Dr. Rigel maintains a private practice in Manhattan where he specializes in skin cancer, sun damage and aging problems of the skin and also lives in Vail, Colorado where he enjoys skiing, golf and fly fishing.
David K. Stone
David K. Stone was appointed as a member of our Board of Directors in December 2011 and as our Chairman as of June 15, 2013. In 2006, Mr. Stone founded Liberty Tree Advisors, LLC, a life sciences investment banking and consulting firm where he is currently a Managing Director. Prior to this, from 2000 to 2006 Mr. Stone was a Managing Director and Partner at Flagship Ventures, a venture capital fund focused in the life sciences industry. From 1989 to 1999, Mr. Stone led the biotechnology equity research team at Cowen & Company. Mr. Stone is currently on the Board of Directors of PAKA Pulmonary Pharmaceuticals and of Seahorse Bioscience, where he is Chairman of the Audit Committee. From 2001 to 2009, he served on the Board of Directors of Oscient Pharmaceuticals, where he served as Chairman from 2005 to 2009.
Kathryn Swintek, was elected to our Board of Directors, in April 2013. Since August 2010, Ms. Swintek has been a Managing Partner and member of the Investment Committee of Golden Seeds Fund 2, and Managing Director of Golden Seeds LLC, an angel investment forum backing women owned or managed early stage and growth companies. Prior to Golden Seeds, Ms. Swintek was a senior executive at BNP Paribas from November 1989 to April 2008, where she most recently served as Managing Director and Global Co-Head of its London-based Financial Sponsors Coverage Group. From 1974 to 1989, Ms. Swintek was a senior executive with Irving Trust Company (now known as BNY Mellon), where she was a Sr. Vice President and held positions in risk management, and acquisition finance, and managed business relationships for the International Division in North Africa and the Near East, as well as in France, where she served as Representative while residing in Paris. Ms. Swintek is Chair of the Governing Board and the Executive Committee of The Committee of 200, a business women’s leadership organization, which she joined in 2003. She serves on the Board of Directors of Trade Settlement, Inc., Turtle & Hughes, Inc., and Open Road Integrated Media, Inc. She is also a member of the Women’s Forum, Women Corporate Directors, and Women Business Leaders of the U.S. Health Care Industry Foundation. Ms. Swintek’s serves as the Chairperson of our Audit Committee.
LuAnn Via was elected to our Board of Directors in April 2012. In November 2012 Ms. Via became President and CEO of Christopher & Banks Corporation, a specialty retailer of women’s clothes; a company operating more than 600 retail stores. Prior to this, Ms. Via served as the President and Chief Executive Officer of Payless ShoeSource, a unit of Collective Brands, Inc., from July 2008 to October 2012 when the company was acquired and taken private. Before joining Payless ShoeSource, from January 2006 Ms. Via served as group divisional President of Lane Bryant and Cacique store chains and as President of Catherines stores, both divisions of Charming Shoppes, Inc. Prior to this, and for more than 20 years, Ms. Via held several leadership positions with a number of top retailers. Ms. Via is a Board member of Christopher & Banks Corporation and a member of The Committee of 200, a business women’s leadership group.
Richard I. Steinhart
Mr. Steinhart’s experience also includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, Mr. Steinhart served on the Board of Manhattan Pharmaceuticals, Inc., a biopharmaceutical company, and was Chairman of its Audit Committee. Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant.
MelaFind® Scientific Advisory Committee
Martin C. Mihm, Jr., MD (Chairman)
Jeffrey P. Callen, MD
Armand B. Cognetta, Jr., MD
Harold S. Rabinovitz, MD
Darrell S. Rigel, MD
Gary Coventry, MS
Michael Greenebaum, PhD
Mark Szober, MS
Diana Garcia Redruello, MIA
Subscribe to MELA Science’s RSS (Really Simple Syndication) feeds to get information delivered directly to your desktop!
Clicking on an RSS link below will provide you with raw XML data of our content. If you do not have a compatible reader installed, you will see XML code in your browser - to view our content, paste the feed address into an RSS reader, or use a browser which supports RSS feeds. See below for additional information on RSS.
Additional Information About RSS
Really Simple Syndication (RSS) is an XML-based format for distributing and aggregating Web content (such as news headlines). Using RSS, web content providers can easily create and disseminate news headlines and URLs. To find more information about common RSS Readers, enter the term “RSS Reader” into an internet search engine.